🔗 Share this article

As the United States continues making unprecedented changes to its vaccine guidelines, a particular individual has emerged unexpectedly: Dr. Tracy Beth Høeg, an American of Danish descent physician and public health researcher who first made her name by expressing skepticism about Covid vaccines in the pandemic and has focused upon possible deaths after Covid vaccination in her recent time at the US Food and Drug Administration (FDA).

Proposed Overhauls to Childhood Immunization Program

Health officials were set to reveal major revisions to the childhood vaccination calendar recently, aligning the US with the Danish immunization schedule, sources say – a major change that would place the US at odds with a large portion of the world with no evidence for benefit. The planned update has been pushed back until the next year.

Instead of the top vaccines chief, Dr. Høeg is set to present at the meeting. She was recently named temporary leader of the FDA’s drug evaluation center, the fifth individual to head the division this year.

A New Direction at the Regulatory Body

The acting appointment could signify a closer partnership between the pharmaceutical and biologics centers as Dr. Høeg and Prasad consolidate power at the regulatory agency – and it suggests a greater focus upon reevaluating already-approved vaccines at the FDA.

Dr. Høeg has often pushed for discontinuing some pediatric vaccine recommendations in the US in order to be more like the Danish model, a society with comprehensive healthcare and a citizenry roughly the population of Wisconsin’s.

To date statements, she has kept her attention on vaccination policy – usually the responsibility of Dr. Prasad, director of the FDA’s CBER – rather than medication approval.

Concerns Over Qualifications

Høeg has little discernible track record in medication creation, regulation or management, which has been typical for former directors of the Center for Biologics Evaluation and Research. She has worked at the FDA as a top consultant to the FDA chief and the vaccine center since spring.

“She appears not to have any of the qualifications” for overseeing the drug-regulation department, remarked Jonathan Howard. “She lacks experience running a randomized controlled trial. She has no expertise in running a sizeable institution. She has no expertise in drug approvals.”

Previous commissioners of CBER would “grasp regulatory frameworks and the research of medication creation”, said Dr. Janet Woodcock. “Clearly, she has not acquired the sort of resume that prior appointees who ran the center have had.”

The drug center has an vast workload at the agency, she pointed out.

“Many people just zeroes in on the novel medication approvals, but the generic drug division approves numerous off-brand pharmaceuticals. There is also a biosimilars division, non-prescription drug unit and so forth, and all of those have to be supervised,” she said. “The thing you don’t keep your eye on, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a significant leadership element to the job, which supervises more than 5,000 personnel. “It is a huge leadership role, if you execute it properly,” the former official said.

Official Statement and Contentious Initiatives

Regarding concerns about Høeg’s qualifications and whether this selection indicates increased cooperation among agency officials on immunizations, a spokesperson responded that the “inquiries are based on incorrect assumptions”.

“Her experience matches the duties of her position,” the spokesperson explained, noting the period Høeg spent guiding the agency head on “drug safety and approval science, including computerized risk analysis and immunization monitoring”.

As the temporary head, Dr. Høeg takes over the commissioner’s controversial expedited review system, a controversial rapid medication authorization process that reportedly troubled her predecessors. “By what process are these drugs being selected for this fast-track system? Who takes the calls?” Howard asked. “There is a lot of lack of transparency happening at the regulatory body right now.”

Overall, he remarked, “the agency looks to be trending towards laxer oversight of all drugs, with the exception of vaccines.”

Public Past Work on Immunizations

Concerning immunizations, Høeg has a clearer, if troubling, track record, some experts said. She published a research paper using unconfirmed public submissions to estimate the frequency of myocarditis following COVID-19 immunization. She consulted for the state of Florida surgeon general Dr. Joseph Ladapo, who allegedly have altered data to imply Covid vaccines are more dangerous than they are.

Included in her “policy goals” for the new administration featured altering regulations for novel immunizations and discontinuing “non-essential” immunizations, she stated after the election on a audio program. At the FDA, Dr. Høeg has reportedly suggested preventing young men from getting COVID-19 vaccines.

“She is an complete ideologue who commences with her beliefs and reverse-engineers to retrofit the evidence in a extremely deceptive, fraudulent fashion,” Howard said.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg joined fellow contrarians, {like|